Levels of Interleukin-17 and Interleukin-23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago

Nobee, Alisa; Justiz-Vaillant, Angel; Akpaka, Patrick Eberechi; Poon-king, Peter

doi:10.4172/2469-9756.1000115

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients experienced symptoms of myositis at 77% and alopecia at 60%. Pleurisy accounted for 43% of patients, while low complement and leukopenia values were 60% and 35%, respectively [5-7]. In the control group those manifestations accounted for less that 5%.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty (30) patients attending the rheumatoid clinic at one of the major regional hospitals in the Caribbean region were recruited. There was no interventional measure; However, the study sought to observe and delineate the presence of IL-17A, 23, and 33 among patients attending a rheumatoid out-patient clinic [5]. By considering the Revised American College of Rheumatology criteria, the diagnosis of lupus was confirmed, and the disease was clinically assessed by SLEDAI score.…”

Section: Methodsmentioning

confidence: 99%

“…A previous research project with fewer subjects was conducted [5]. This prospective, cross-sectional, observational study was performed.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Justiz-Vaillant¹,

Nobee

2020

Preprint

View full text Add to dashboard Cite

The systemic lupus erythematosus (SLE) is the greatest manifestation of autoimmunity. It is characterized by the presence of cytokines, including type I and II interferons, interleukin-6 (IL-6), IL-1, and tumor necrosis factor-alpha (TNF-α), the immunomodulatory cytokines like IL-10 and TGF-β, be essential players in SLE. Additionally, T-cell-derived cytokines like IL-17A, IL-21, and IL-2 are dysregulated in SLE. In this paper, a prospective cross-sectional and observational study was done. It was measured the levels of 3 essential cytokines in SLE: IL-17A, IL-23, and IL-33 using three enzyme-linked immunosorbent assays (ELISA). Thirty (30) patients attending the rheumatoid clinic at one of the major regional hospitals in the Caribbean region were recruited. Mostly females above the childbearing age give their consent to be included in the study and other 30 healthy patients were used a control. Of all the SLE patients, 15 (50%) patients were of Afro-Caribbean descent, 12 (40%) of patients were of Indo-Caribbean descent, and 3 (10%) of patients were of mixed descent. Nineteen (63%) healthy controls were females, and 11 (37%) were males. The results showed that serum IL-17A and IL-23 were more significantly higher in SLE patients than controls (P<0.01); however, there was no statistically significant difference between IL-33 levels between SLE patients and healthy controls. The study showed no correlation between serum IL-17A and IL-23 in SLE patients as judged by the result of the Pearson correlation coefficient (r=0.308, p>0.05). It also showed that serum IL-17A and IL-23 levels positively correlate to the SLE disease activity index 2000 score (SLEDAI score). Nevertheless, IL-33 levels show no correlation with the SLEDAI score. In this study, higher cytokines were reported mostly in patients between the ages of 25 to 30-year-old and Afro-Caribbean descent.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Justiz-Vaillant¹,

Nobee

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…This is the case for a woman with well-known SLE that has been previously reported [11,12]. A 23-year-old white woman was sent to the Freyre de Andrade Hospital, Havana City, Cuba, with symptoms of malaise.…”

Section: Case Presentation Onementioning

confidence: 78%

“…Recurrent chest infections may be a late clinical manifestation of this autoimmune disease. Garcia-Guevara et al (2018) reported that pneumonia remains the leading cause of mortality in patients with systemic lupus erythematosus (SLE), and the most common bacteria isolated are S. aureus, but other genera of bacteria have been cited [10][11].…”

Section: Discussionmentioning

confidence: 99%

Systemic Lupus Erythematosus and Its Treatment With Intravenous Immunoglobulins (IVIG)

A¹,

B²

2021

Preprint

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by a broad array of clinical signs. In this study, we aimed to use intravenous immunoglobulins (IVIG), called intacglobin, as a monotherapy to manage SLE in three patients. Laboratory investigations for SLE diagnosis were performed, including the detection of anti-nuclear antibodies (ANA) and SLE confirmation by detecting high titers of anti-dsDNA antibodies. C3 and C4 serum levels were assessed, as well as the determination of immunoglobulins. The SLEDAI score was measured to determine whether a significant degree of disease activity existed and as a prognostic value. The evaluation of any chest infection was performed by chest-X-ray. The patients were treated with five–ten g/day of IVIG for six consecutive days, followed by five–ten g/month. Immunological evaluation demonstrated that patients presented with a flare of SLE with high titers of ANA and anti-dsDNA antibodies, low C3 and C4, and elevated immunoglobulin levels. The SLEDAI score falls from 10 to below 3, and chest infections in some patients are cleared up. The postulated mechanisms of action of IVIG demonstrated that it could be used as an immunosuppressor, immunomodulator, and antimicrobial agent in patients with SLE.

show abstract

Cytokines (IL-17, IL-23 and IL-33) in Adult Patients with Systemic Lupus Erythematosus in Trinidad and Tobago

Vaillant

Akpaka

2022

JAMMR

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is the most common autoimmune disease. It is characterized by the presence of hundreds of autoantibodies against many organs and tissues, including the presence of a large number of autoantibodies, which are specific to self-antigens mainly of nuclear origin such as Smith antigen, double-stranded DNA (dsDNA), anti-Sjögren’s syndrome-related antigen A and B (SSA/Ro and SSB/La, respectively) and ribonucleoproteins, which are the hallmarks of the disease. Type I and II interferons, interleukin-6 (IL-6), IL-1, tumor necrosis factor-alpha (TNF-α), and immunomodulatory cytokines such as IL-10 and TGF-β are essential players in SLE. Additionally, T-cell-derived cytokines such as IL-17, IL-21, and IL-2 are dysregulated in SLE. In this study among cohorts of 60 individuals attending the hospital clinics in Trinidad and Tobago, blood samples were analyzed and the levels of the essential cytokines were measured using SLE Disease Activity Index (SLEDAI) 2000 score. The results confirmed that serum IL-17 and IL-23 levels were positively correlated with the SLE Disease Activity Index (SLEDAI) 2000 score in these patients. These findings have diagnostic and therapeutic implications. However, more work must be done targeting other cytokines relevant to autoimmunity and SLE in particular. Interleulin-33 is not an SLE marker, as has been noted in other populations.

show abstract

Levels of Interleukin-17 and Interleukin-23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago

Cited by 3 publications

References 0 publications

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Systemic Lupus Erythematosus and Its Treatment With Intravenous Immunoglobulins (IVIG)

Cytokines (IL-17, IL-23 and IL-33) in Adult Patients with Systemic Lupus Erythematosus in Trinidad and Tobago

Contact Info

Product

Resources

About